← Back

Wire · regulatory

Capricor's regulatory odyssey for DMD cell therapy hits second FDA rejection

Published

21 November 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The FDA rejected Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy for the second time, citing insufficient evidence of effectiveness and other clinical deficiencies. Capricor disputes the FDA's assessment despite positive trial data and plans to review the agency's complete response letter to determine next steps.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a tougher regulatory hurdle after the FDA rejects a high-profile cell therapy twice despite positive trials. Rethink your strategy for clinical data presentation and prepare for prolonged review cycles.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-rejectionduchenne-muscular-dystrophycell-therapyclinical-trialsregulatory-review